We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Billionaire and television personality Mark Cuban has unveiled the Mark Cuban Cost Plus Drug Company, which aims to produce low-cost versions of expensive generics. Read More
UK drugmaker Synairgen has dosed the first patient in a global phase 3 trial evaluating an inhaled formulation of interferon beta-1a, SNG001, for treating hospitalized COVID-19 patients who require supplemental oxygen. Read More
Oxford Immunotec is teaming up with Valneva to help the French biotech with a phase 1/2 UK trial of its inactivated COVID-19 vaccine candidate, VLA2001. Read More
FDA veteran Janet Woodcock has reportedly been short-listed by the incoming Biden administration to serve as the agency’s next commissioner and will also likely serve as acting chief until the position is filled. Read More
In observance of Martin Luther King Jr. Day, Drug Industry Daily will not be published Monday, Jan. 18. The next issue will be published Tuesday, Jan. 19. Read More
The Endocrine Society, a large physicians’ group, is calling on policymakers to include government negotiation as part of an overall strategy to reduce insulin prices. Read More
The Pharmaceutical Care Management Association (PCMA) has filed a lawsuit to halt implementation of President Trump’s drug pricing policy that aims to prevent drugmakers and pharmacy benefit managers from negotiating rebates on prescription medicines. Read More
Eli Lilly CEO David Ricks has expressed concern that the new variant of the coronavirus that causes COVID-19 first reported in South Africa might be resistant to the company’s antibody treatment bamlanivimab. Read More
Brazil’s Butantan Institute reported that Sinovac’s COVID-19 vaccine, CoronaVac, demonstrated an overall efficacy of only 50.38 percent in a phase 3 trial, putting it barely over the World Health Organization’s 50 percent efficacy threshold for approval. Read More